Mahathi Sama

Sama Therapeutics is a precision neuropsychiatry company developing an AI-driven platform to personalize the treatment of mental health disorders. The company's proprietary iMAGINE platform integrates multi-modal data, including EEG biomarkers and clinical assessments, to predict patient response to various therapies. By leveraging machine learning, Sama Therapeutics aims to transition psychiatry from a trial-and-error model to a data-driven, personalized medicine approach. Their primary focus includes indications such as major depressive disorder, PTSD, and anxiety. The company frequently collaborates with therapeutic developers to optimize clinical trial outcomes and treatment selection.